Compare PTEN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTEN | CPRX |
|---|---|---|
| Founded | 1978 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 1995 | 2006 |
| Metric | PTEN | CPRX |
|---|---|---|
| Price | $9.28 | $31.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $10.80 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 10.5M | 1.8M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ 90.16 | 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $4,826,624,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | $4.34 | $10.51 |
| P/E Ratio | ★ N/A | $62.97 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $5.10 | $19.05 |
| 52 Week High | $13.08 | $32.56 |
| Indicator | PTEN | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 69.77 |
| Support Level | $9.26 | $31.25 |
| Resistance Level | $12.59 | $32.56 |
| Average True Range (ATR) | 0.42 | 0.04 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 49.13 | 85.71 |
Patterson-UTI Energy Inc is a Texas based provider of drilling and completion services to oil and natural gas exploration and production companies, offering contract drilling, integrated well completion, directional drilling services, and specialized drill bit solutions. The Company operates through three segments: Drilling Services, Completion Services, and Drilling Products. Drilling Services includes contract and directional drilling, Completion Services generates maximum revenue and includes hydraulic fracturing and related support services, and Drilling Products includes the manufacturing and distribution of drill bits. The Company operates in the United States, Canada, Colombia, and Other Countries, with the majority of revenue coming from the United States.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.